Rani Therapeutics Holdings, Inc. 8-K

What Happened
Rani Therapeutics Holdings, Inc. announced on June 29, 2026 that Nicholas M. Maestas has been appointed Chief Financial Officer (principal financial and accounting officer), succeeding Svai Sanford. Mr. Maestas’ appointment is effective June 29, 2026. He most recently served as CFO and Head of Corporate Strategy at Tempest Therapeutics and has prior finance roles at Alector and Immune Design.

Key Details

• Start date: June 29, 2026.
• Compensation: $500,000 annual base salary and eligible for an annual bonus with a target equal to 75% of base salary.
• Equity award: Non‑qualified stock option to purchase 2,000,000 shares under the Company’s 2026 Equity Inducement Plan; vests over four years (25% at one year, remaining 75% vesting equally over the next 36 months).
• Inducement plan: Board approved the 2026 Equity Inducement Plan on June 28, 2026 and reserved 5,500,000 Class A shares for inducement awards to new hires (Nasdaq Rule 5635(c)(4) exemption; shareholder approval not required).
• Other: Mr. Maestas will be eligible for the Company’s Severance and Change in Control Plan and will enter the standard indemnification agreement. No family relationships or outside arrangements were disclosed.

Why It Matters
This filing signals a leadership change in Rani’s finance function with an experienced biotech finance executive taking over as CFO. The compensation package includes a sizable equity inducement (2.0M‑share option) and participation in severance/change‑in‑control protections, which are relevant to assessing future executive costs and potential share dilution. Investors should note the 5.5M shares reserved under the Inducement Plan and the specific terms of Mr. Maestas’ option when evaluating dilution and executive incentives.